Risk factors for brain metastases in patients with metastatic colorectal cancer

被引:26
作者
Christensen, Troels Dreier [1 ]
Palshof, Jesper Andreas [1 ]
Larsen, Finn Ole [1 ]
Hogdall, Estrid [2 ]
Poulsen, Tim Svenstrup [2 ]
Pfeiffer, Per [3 ]
Jensen, Benny Vittrup [1 ]
Yilmaz, Mette Karen [4 ]
Christensen, Ib Jarle [2 ]
Nielsen, Dorte [1 ]
机构
[1] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Oncol, Herlev, Denmark
[2] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Pathol, Herlev, Denmark
[3] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[4] Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark
关键词
PROGNOSTIC-FACTORS; LIVER METASTASES; SURVIVAL; RESECTION; MUTATION; PATTERN; RECURRENCE; FEATURES; SPREAD;
D O I
10.1080/0284186X.2017.1290272
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Brain metastases (BM) from colorectal cancer (CRC) are rare, but the incidence is suspected to rise as treatment of metastatic (m) CRC improves. The aim of this study was to identify possible biological and clinical characteristics at initial presentation of mCRC that could predict later risk of developing BM. Furthermore, we wished to estimate the incidence of BM in long-term surviving patients. Material and methods: We conducted a retrospective study on a Danish multicenter cohort of patients with mCRC who received cetuximab and irinotecan (Cetlri) as third-line treatment. All patients had previously progression on 5-FU, irinotecan and oxaliplatin containing regimens and received Cetlri treatment independent of RAS mutations status. We subsequently performed KRAS, NRAS, BRAF, PIK3CA, PTEN, ERBB2 and EGFR sequencing of DNA extracted from primary tumor tissue. Results: Totally, 480 patients were included in our study. BM were diagnosed in 42 [8.8%; 95% confidence interval (CI) 6.4-11.6%] patients. Patients with BM had a significantly longer survival from mCRC diagnosis than non-BM patients (median=32 versus 28 months, p = 0.001). On univariate cox regression analysis, the risk of developing BM was significantly increased in patients with rectal cancer (HR = 3.9; 95% CI = 1.2-13.3), metachronous metastatic disease (HR = 2.3; 95% CI = 1.2-4.4) and lung metastases (HR = 4.2; 95% CI = 2.2-7.9). On multivariate cox regression analysis only lung metastases were significantly associated BM (HR = 3.5; 95% CI = 1.8-6.8 ). None of the investigated mutations were associated with BM. Conclusion: The incidence of BM was 8.8% in patients with mCRC who received third-line therapy. The most important risk factor for developing BM was lung metastases. Furthermore, rectal cancer, metachronous metastatic disease and long survival were linked to BM development.
引用
收藏
页码:639 / 645
页数:7
相关论文
共 50 条
  • [21] METASTATIC MELANOMA: PROGNOSTIC FACTORS AND SURVIVAL IN PATIENTS WITH BRAIN METASTASES
    Frinton, Emily
    Board, Ruth
    ANTICANCER RESEARCH, 2016, 36 (12) : 6717 - 6717
  • [22] The Validity of Clinical Risk Score for Patients Undergoing Liver Resection for Colorectal Metastases
    Ivanecz, Arpad
    Potrc, Stojan
    Horvat, Matjaz
    Jagric, Tomaz
    Gadzijev, Eldar
    HEPATO-GASTROENTEROLOGY, 2009, 56 (94-95) : 1452 - 1458
  • [23] High risk factors of brain metastases in 295 patients with advanced breast cancer
    Yan Min
    Lu Hui-min
    Liu Zhen-zhen
    Liu Hui
    Zhang Meng-wei
    Sun Xi-bin
    Cui Shu-de
    CHINESE MEDICAL JOURNAL, 2013, 126 (07) : 1269 - 1275
  • [24] Metastatic melanoma: prognostic factors and survival in patients with brain metastases
    E. Frinton
    D. Tong
    J. Tan
    G. Read
    V. Kumar
    S. Kennedy
    C. Lim
    R. E. Board
    Journal of Neuro-Oncology, 2017, 135 : 507 - 512
  • [25] Inflammatory breast cancer and development of brain metastases: risk factors and outcomes
    Warren, Laura E. G.
    Guo, Hao
    Regan, Meredith M.
    Nakhlis, Faina
    Yeh, Eren D.
    Jacene, Heather A.
    Hirshfield-Bartek, Judi
    Overmoyer, Beth A.
    Bellon, Jennifer R.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (01) : 225 - 232
  • [26] Prognostic factors for ovarian metastases in colorectal cancer patients
    Chen, Chao
    Wang, Da
    Ge, Xiaoxu
    Wang, Jian
    Huang, Yuhuai
    Ling, Tianyi
    Jin, Tian
    Yang, Jinhua
    Wang, Fengping
    Wu, Weihong
    Sun, Lifeng
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [27] Risk factors for survival following recurrence after first liver resection for colorectal cancer liver metastases
    Serrano, Pablo E.
    Gu, Chu-Shu
    Husien, Mohamed
    Jalink, Diederick
    Ritter, Anne
    Martel, Guillaume
    Tsang, Melanie E.
    Law, Calvin H.
    Hallet, Julie
    McAlister, Vivian
    Sela, Nathalie
    Solomon, Hannah
    Moulton, Carol-Anne
    Gallinger, Steven
    Levine, Mark
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (08) : 1420 - 1426
  • [28] Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience
    Gossling, Gustavo C. L.
    Chedid, Marcio F.
    Pereira, Fernando S.
    da Silva, Rafaela K.
    Andrade, Leonardo B.
    Peruzzo, Nicolas
    Saueressig, Mauricio G.
    Schwartsmann, Gilberto
    Parikh, Aparna R.
    ONCOLOGIST, 2021, 26 (09) : E1581 - E1588
  • [29] Patients with brain metastases from gastric cancer
    Yang, Yu
    Yang, Yang
    Chen, Zhendong
    TUMORI JOURNAL, 2023, 109 (02): : 164 - 172
  • [30] Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases
    Bergen, E. S.
    Scherleitner, P.
    Ferreira, P.
    Kiesel, B.
    Mueller, C.
    Widhalm, G.
    Dieckmann, K.
    Prager, G.
    Preusser, M.
    Berghoff, A. S.
    ESMO OPEN, 2021, 6 (03)